Celltrion, Inc. Stock Korea S.E.
Equities
068270
KR7068270008
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- KRW | - |
Apr. 24 | Market Share of Celltrion’s Remsima Rises to 74% in Europe | MT |
Apr. 17 | Celltrion, Inc. announces an Equity Buyback for 436,047 shares. | CI |
Sales 2024 * | 3,428B 2.5B | Sales 2025 * | 4,172B 3.04B | Capitalization | 37,206B 27.09B |
---|---|---|---|---|---|
Net income 2024 * | 505B 368M | Net income 2025 * | 1,099B 800M | EV / Sales 2024 * | 11 x |
Net Debt 2024 * | 656B 477M | Net Debt 2025 * | 297B 216M | EV / Sales 2025 * | 8.99 x |
P/E ratio 2024 * |
71.9
x | P/E ratio 2025 * |
33.4
x | Employees | - |
Yield 2024 * |
0.23% | Yield 2025 * |
0.24% | Free-Float | 63.31% |
Managers | Title | Age | Since |
---|---|---|---|
Wu-Sung Ki
CEO | Chief Executive Officer | 62 | 07-04-23 |
Ho-Seop Lee
DFI | Director of Finance/CFO | 49 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Soon-Woo Lee
BRD | Director/Board Member | 73 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Jong-Seok Lee
BRD | Director/Board Member | 72 | 14-12-07 |
1st Jan change | Capi. | |
---|---|---|
+4.09% | 43.84B | |
+46.90% | 41.25B | |
+9.45% | 41.68B | |
+9.32% | 25.53B | |
-24.87% | 18.18B | |
+29.70% | 12.29B | |
+1.28% | 12.29B | |
+7.78% | 11.15B | |
-17.68% | 9.98B |
- Stock Market
- Equities
- A068270 Stock
- 068270 Stock